Barclays Keeps Their Sell Rating on Molina Healthcare (MOH)
Barclays analyst Andrew Mok CFA maintained a Sell rating on Molina Healthcare today and set a price target of $133.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mok CFA covers the Healthcare sector, focusing on stocks such as Brookdale Senior Living, Encompass Health, and Universal Health. According to TipRanks, Mok CFA has an average return of -2.6% and a 45.28% success rate on recommended stocks.
In addition to Barclays, Molina Healthcare also received a Sell from Bank of America Securities’s Kevin Fischbeck in a report issued on April 7. However, on April 6, Bernstein assigned a Buy rating to Molina Healthcare (NYSE: MOH).
Based on Molina Healthcare’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $11.38 billion and a GAAP net loss of $160 million. In comparison, last year the company earned a revenue of $10.5 billion and had a net profit of $251 million
Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is neutral on the stock. Last month, Ronna Romney, a Director at MOH sold 506.00 shares for a total of $74,341.52.
Read More on MOH:
Disclaimer & DisclosureReport an Issue
- Midday Fly By: Health insurers get ‘positive surprise’ from CMS
- Deutsche sees margin pressure despite ‘positive surprise’ from CMS
- Molina Healthcare price target raised to $152 from $145 at BofA
- Closing Bell Movers: Health insurers rise on higher Medicare rate hike
- CMS finalizes 2027 Medicare Advantage payments with 2.48% increase
